Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-09-04
2007-09-04
Carr, Deborah D. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
10332353
ABSTRACT:
The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect for example by induction of differentiation and/or apoptosis in transformed cells.
REFERENCES:
patent: 5672746 (1997-09-01), Nau et al.
patent: 5858365 (1999-01-01), Faller
patent: WO 96/06821 (1996-03-01), None
patent: WO 97/11366 (1997-03-01), None
patent: WO 97/35990 (1997-10-01), None
patent: WO 98/29114 (1998-07-01), None
patent: WO 99/23885 (1999-05-01), None
patent: WO 99/37150 (1999-07-01), None
patent: WO 02/007722 (2002-01-01), None
Wang, JF et al.,Molecular Pharmacology, 55 (3). 521-7, (1999).
Wlodarczyk BC et al.,Teratology, 54 (6), 284-97, (1996).
Manji HK et al.,Journal of Clinical Psychiatry, 60 Suppl 2, 27-39, (1999).
Rogiers V et al.,European Journal of Biochemistry, 231 (2), 337-43, (1995).
Chen G et al.,Journal of Neurochemistry, 72 (2), 879-82, (1999).
Sands SA et al., Neuropsychopharmacology, 22 (1), 27-35, (2000).
Yoshida M,The Journal of Biological Chemistry, vol. 265, No. 28, 17174-17179, (1990).
Fischkoff S and Walter E Jr.,Journal of Biological Response Modifiers, 3:132-137, (1984)).
Skladchikova G et al.,NeuroToxicology, 19 (3), 357-370, (1998).
Nordenberg J et al.,Biochemical Pharmacology, vol. 58, pp. 1229-1236, (1999).
Tittle T and Schaumann B,Epilepsia, 33 (4), 729-735, (1992).
Mori H et al., Folia Pharmacologica Japonica, 74 (8), 907-23, (1978).
Nieder C et al.,Strahlentherapie und Onkologie, vol. 176, No. 6, (Jun. 2000).
Letizia C et al.,European Journal of Internal Medicine, 5: 325-328 (1994).
Göttlicher M et al., “Cellular Actions of Valproic Acid and Its Teratogenic Derivatives: Activation of Peroxisome Proliferator Activated Receptors (PPARs) and Differentiation of Teratocarcinoma Cells,” XP-002166104, abstract.
International Search Report for PCT Patent Application No. PCT/EP01/07704, mailed May 24, 2002.
International Preliminary Examination Report for PCT Application No. PCT/EP01/07704, mailed Oct. 14, 2002.
European Search Report for European Application No. EP 00 11 4088, report completed Sep. 12, 2001.
Xu et al., “Coactivator and Corepressor Complexes in Nuclear Receptor Function,”Current Opinion in Genetics&Development, 9, 140-147, (1999).
Warrell,, Jr. et al, “Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase,”Accelerated Discovery, vol. 90, No. 21, 1621-1625, (1998).
Redner et al., “Chromatin Remodeling and Leukemia: New Therapeutic Paradigms,”Blood, vol. 94 No. 2, 417-428, (1999).
Nau et al., “Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms,”Pharmacology&Toxicology, vol. 69, 310-321 (1991).
Lampen et al., New Molecular Bioassays for the Estimation of the Teratogenic Potency of Valproic Acid Derivatives in Vitro: Activation of the Peroxisomal Proliferator-Activated Receptor (PPARδ),Toxicology and Applied Pharmacology, vol. 160, 238-249 (1999).
Chybicka et al., “The Results of Myelodysplastic Syndrome (MDS) Therapy obtained by the Polish Childrens Leukemia/Lymphoma Study Group,”Pol. Arch. Med. Wewn, 155-158 (1998).
Werling et al., Induction of Differentiation in F9 Cells and Activation of Peroxisome Proliferator-Activated Receptor δ by Valproic Acid and its Teratogenic Derivatives,Molecular Pharmacology, vol. 59, 1269-1276, (2001).
Abbosh PH, Nephew KP.: “Multiple signaling pathways converge on beta-catenin in thyroid cancer”,Thyroid. Jun. 2005;15(6):551-61. Review.
Curti BD Physical barriers to drug delivery in tumors. “Crit. Rev. Oncol. Hematol.” 1993, 14:29-39.
Darbinian et al: “Growth inhibition of glioblastoma cells by human Pur(alpha)”.J. Cell Physiol. 2001189(3):334-340.
Gura T, “Systems for identifying new drugs are often faulty”.Science, 1997, 278:1041-1042.
Hartwell LH et al “Integrating genetic approaches into the discovery of anticancer drugs”.Science1997, 278:1064-1068.
Jain RK. “Barriers to drug delivery in solid tumors”.Sci. Am.1994, 271:58-65.
Leung SK, Ohh M.: “Playing Tag with HIF: The VHL Story”,J Biomed Biotechnol.2002;2(3):131-135.
Lian Z, Di Cristofano A.: “Class reunion: PTEN joins the nuclear crew”.Oncogene.Nov. 14, 2005;24(50):7394-400.
Litzow MR.: “Imatinib resistance: obstacles and opportunities”.Arch Pathol Lab Med.May 2006;130(5):669-79.
Oliva E, Sarrio D, Brachtel EF, Sanchez-Estevez C, Soslow RA, Moreno-Bueno G, Palacios J.: “High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary”,J Pathol.Apr. 2006; 208 (5):708-13.
Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid Km Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM.: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta. Jul. 18, 2002;1587 (2-3):194-205.
Polakis P.: “Wnt signaling and cancer”.Genes Dev.Aug. 1, 2000;14(15):1837-51.
Verras M, Sun Z.: “Roles and regulation of Wnt signaling and beta-catenin in prostate cancer”.Cancer Lett.Jun. 8, 2006;237(1):22-32. Epub Jul. 14, 2005.
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M.: “Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis”.Cancer Cell. May 2004;5(5):455-63.
Göttlicher Martin
Groner Bernd
Heinzel Thorsten
Herrlich Peter
Carr Deborah D.
Georg-Speyter-Haus Chemotherapeutisches Forschungsinstitut
Reed Smith LLP
LandOfFree
Valproic acid and derivatives thereof as histone deacetylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Valproic acid and derivatives thereof as histone deacetylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Valproic acid and derivatives thereof as histone deacetylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3742138